Tenecteplase versus alteplase in stroke thrombolysis: An individual patient data meta-analysis of randomized controlled trials

International Journal of Stroke

Volumn 11, Issue 5, 2016, Pages 534-543

  Huang, Xuya ^a   MacIsaac, Rachael ^b   Thompson, John L P ^c   Levin, Bruce ^c   Buchsbaum, Richard ^c   Haley, E Clarke ^d   Levi, Christopher ^e   Campbell, Bruce ^f   Bladin, Christopher ^g   Parsons, Mark ^e   Muir, Keith W ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

^c Och Spine at New York Presbyterian Hospitals   (United States)

^d UNIVERSITY OF VIRGINIA   (United States)

^e UNIVERSITY OF NEWCASTLE   (Australia)

^f ROYAL MELBOURNE HOSPITAL   (Australia)

^g MONASH UNIVERSITY   (Australia)

Author keywords

Acute stroke therapy; Alteplase; Intracerebral hemorrhage; Meta analysis; Tenecteplase; Thrombolysis

Indexed keywords

ALTEPLASE; TENECTEPLASE; FIBRINOLYTIC AGENT; TISSUE PLASMINOGEN ACTIVATOR;

ARTICLE; BLOOD CLOT LYSIS; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; CLINICAL EFFECTIVENESS; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; HUMAN; META ANALYSIS; MORTALITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT PLANNING; AGED; COMPARATIVE STUDY; FEMALE; FIBRINOLYTIC THERAPY; MALE; STROKE;

AGED; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; MALE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STROKE; THROMBOLYTIC THERAPY; TISSUE PLASMINOGEN ACTIVATOR;

EID: 84970021312     PISSN: 17474930     EISSN: 17474949     Source Type: Journal    
DOI: 10.1177/1747493016641112     Document Type: Article

References (20)

1. Keyt BA, Paoni NF, Refino CJ, et al. A faster-acting and more potent form of tissue plasminogen activator. Proc Natl Acad Sci USA 1994; 91: 3670-3674
2. Benedict CR, Refino CJ, Keyt BA, et al. New variant of human tissue plasminogen activator (TPA) with enhanced efficacy and lower incidence of bleeding compared with recombinant human TPA. Circulation 1995; 92: 3032-3040
3. Assessment of the Safety and Efficacy of a New Thrombolytic (ASSENT-2) Investigators. Singlebolus tenecteplase compared with frontloaded alteplase in acute myocardial infarction: the ASSENT-2 doubleblind randomised trial. Lancet 1999; 354: 716-722
4. Hacke W, Kaste M, Fieschi C, et al. Randomised doubleblind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Lancet 1998; 352: 1245-1251
5. Haley EC, Thompson JLP, Grotta JC, et al. Phase IIB/III trial of tenecteplase in acute ischemic stroke results of a prematurely terminated randomized clinical trial. Stroke 2010; 41: 707-711
6. Parsons MW, Spratt N, Bivard A, et al. A randomised trial of tenecteplase versus alteplase for acute ischaemic stroke. N Engl J Med 2012; 366: 1099-1107
7. Haley EC, Lyden PD, Johnston KC and Hemmen TM; The TNK in Stroke Investigators. A pilot dose-escalation safety study of tenecteplase in acute ischemic stroke. Stroke 2005; 36: 607-612
8. Parsons MW, Miteff F, Bateman GA, Spratt N, Loiselle A and Attia J. Acute ischemic stroke: imaging guided tenecteplase treatment in an extended time window. Neurology 2009; 72: 915-921
9. Molina CA, Ribo M, Rubiera M, et al. TNK induces faster MCA recanalization and leads to better short and long-term clinical outcome than native tPA, the TNK-TPA Reperfusion Stroke Study. Stroke 2008; 39: 563
10. Huang X, Cheripelli BK, Lloyd SM, et al. Alteplase versus tenecteplase for thrombolysis after ischaemic stroke (ATTEST): a phase 2, randomised, open-label, blinded endpoint study. Lancet Neurol 2015; 14: 368-376
11. Haley EC, Levy DEJ, Brott TG, et al. Urgent therapy for stroke. Part II. Pilot study of tissue plasminogen activator administered 91-180 minutes from onset. Stroke 1992; 23: 641-645
12. Brott TG, Haley EC, Levy DE, et al. Urgent therapy for stroke. Part I. Pilot study of tissue plasminogen activator administered within 90 minutes. Stroke 1992; 23: 632-640
13. Hacke W, Albers G, Al-Rawi Y, et al. The desmoteplase in acute ischemic stroke trial (DIAS): a phase II MRIbased 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase. Stroke 2005; 36: 66-73
14. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute iachaemic stroke. N Engl J Med 1995; 333: 1581-1587
15. Hacke W, Kaste M, Fieschi C, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS). JAMA 1995; 274: 1017-1025
16. TEMPO-2 (TNK-tPA evaluation for minor ischemic stroke with proven occlusion), http://www.ucalgary.ca/quicr/research#TEMPO-2 (accessed 14 March 2015)
17. Tenecteplase versus Alteplase for Stroke Thrombolysis Evaluation (TASTE) Trial Australian New Zealand Clinical trials Registry. https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=ACTRN 12613000243718 (2014, accessed 14 March 2015)
18. Logallo N, Kvistad C, Nacu A, et al. The Norwegian tenecteplase stroke trial (NOR-TEST): randomised controlled trial of tenecteplase vs. alteplase in acute ischaemic stroke. BMC Neurol 2014; 14: 106
19. Coutts SB, Dubuc V, Mandzia J, et al. Tenecteplase-tissue-type plasminogen activator evaluation for minor ischemic stroke with proven occlusion. Stroke 2015; 46: 769-774
20. Wahlgren N, Ahmed N, Davalos A, Ford GA, Grond M and Hacke W. Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITSMOST): an observational study. Lancet 2007; 369: 275-282